← Back to guidelines
Anesthesiology5 papers

Mycetoma caused by Madurella grisea

Last edited: 2 h ago

Overview

Mycetoma caused by Madurella grisea is a chronic, granulomatous infection characterized by localized swelling, draining sinuses, and the formation of distinctive grains in the affected tissue, typically involving the skin and underlying structures of the extremities. This condition predominantly affects individuals in rural agricultural settings, particularly in tropical and subtropical regions, with a notable predilection for men aged 20 to 50 years who engage in activities exposing their limbs to soil and vegetation. Early diagnosis and intervention are crucial due to the progressive nature of the disease, which can lead to significant functional impairment if left untreated. Understanding the clinical presentation and prompt management are essential for clinicians to mitigate long-term disability and improve patient outcomes 15.

Pathophysiology

Madurella grisea infection initiates with traumatic implantation of fungal spores into the skin, often through minor injuries. The fungus then invades the subcutaneous tissues, leading to a chronic inflammatory response characterized by the formation of granulomas. These granulomas evolve into characteristic "grains," which are aggregates of fungal cells surrounded by inflammatory cells and host tissue debris. The continuous proliferation of these grains and the associated inflammatory reaction cause progressive tissue destruction, leading to the hallmark clinical features of mycetoma, including painless swelling, sinus tract formation, and the discharge of black or white grains. Molecularly, the pathogenicity of M. grisea involves its ability to evade host immune responses and manipulate cellular signaling pathways, contributing to its persistence and the chronic nature of the infection 5.

Epidemiology

Mycetoma caused by Madurella grisea has a global distribution but is most prevalent in tropical and subtropical regions, particularly in Africa, India, and Central and South America. The exact incidence is challenging to determine due to underreporting and diagnostic challenges, but it is estimated to affect thousands annually. The disease predominantly affects young to middle-aged adults, with a male-to-female ratio often exceeding 10:1, reflecting occupational exposures. Risk factors include agricultural activities, manual labor involving soil contact, and poor wound care practices. Over time, there has been a gradual increase in reported cases linked to improved awareness and diagnostic capabilities, though regional disparities persist 15.

Clinical Presentation

Patients typically present with painless swelling in the affected limb, often starting at the site of initial trauma. Over time, the swelling becomes more pronounced and may be associated with the development of multiple sinuses that discharge characteristic grains, which can be black (indicative of Madurella species) or white (suggestive of other causative agents like Actinomadura or Nocardia). Pain is usually minimal initially but can increase as the disease progresses and involves deeper structures such as bones and tendons. Red-flag features include rapid progression, systemic symptoms like fever, and involvement of vital structures, which necessitate urgent referral for comprehensive management 5.

Diagnosis

The diagnosis of mycetoma caused by Madurella grisea involves a combination of clinical evaluation and laboratory investigations. Key steps include:

  • Clinical Assessment: Detailed history focusing on occupational exposures and initial injury.
  • Physical Examination: Identification of characteristic swelling, sinuses, and grain discharge.
  • Microbiological Examination:
  • - Grain Culture: Culturing grains from discharge on specialized media like Sabouraud dextrose agar with chloramphenicol and cycloheximide. - Histopathology: Biopsy samples stained with periodic acid-Schiff (PAS) or Grocott's methenamine silver (GMS) stain to visualize fungal elements.
  • Imaging:
  • - Radiography: Useful for detecting bone involvement. - MRI/CT: Provides detailed images of soft tissue and bone involvement, aiding in staging the disease.
  • Differential Diagnosis:
  • - Osteomyelitis: Typically presents with more pain and systemic symptoms. - Tuberculosis: Granulomas may be present but grains are absent. - Foreign Body Granuloma: Absence of characteristic grains and different clinical history. - Lymphoma: Absence of fungal elements on histopathology and culture 5.

    Management

    First-Line Treatment

  • Amphotericin B: Intravenous infusion, typically 0.5-1 mg/kg/day, adjusted based on renal function. Duration varies but often several months.
  • Itraconazole: Oral, 200 mg twice daily. Effective for less severe cases or as maintenance therapy post-intravenous treatment. Duration: 6-12 months.
  • Monitoring: Regular clinical assessments, periodic imaging, and blood tests to monitor for side effects and treatment efficacy 5.
  • Second-Line Treatment

  • Terbinafine: Oral, 250 mg twice daily. Considered when itraconazole fails or is contraindicated. Duration: 6-12 months.
  • Posaconazole: Oral, 400 mg twice daily. Alternative for refractory cases. Duration: Tailored based on response.
  • Monitoring: Similar to first-line, with additional vigilance for drug interactions and specific side effects 5.
  • Refractory or Specialist Escalation

  • Combination Therapy: May include a combination of antifungal agents tailored by infectious disease specialists.
  • Surgical Intervention: Debridement or amputation in cases of extensive bone involvement or severe functional impairment.
  • Referral: To specialized centers for advanced imaging, surgical management, and multidisciplinary care.
  • Monitoring: Intensive follow-up with multidisciplinary teams, including orthopedic and infectious disease specialists 5.
  • Complications

  • Bone Involvement: Progressive bone destruction leading to deformities and functional loss.
  • Joint Damage: Chronic inflammation can result in joint ankylosis or severe arthritis.
  • Systemic Spread: Rare but serious, potentially leading to sepsis or disseminated infection.
  • Management Triggers: Delayed diagnosis, inadequate treatment, and lack of surgical intervention when indicated. Early referral to specialists is crucial to prevent these complications 5.
  • Prognosis & Follow-up

    The prognosis for mycetoma caused by Madurella grisea varies widely depending on the extent of disease at diagnosis and the timeliness and efficacy of treatment. Early intervention significantly improves outcomes, reducing the risk of severe deformities and functional impairment. Prognostic indicators include the absence of bone involvement at diagnosis and successful eradication of the fungus. Recommended follow-up intervals include:
  • Initial Phase: Monthly clinical assessments and imaging every 3-6 months.
  • Maintenance Phase: Every 6-12 months, adjusting based on clinical stability and treatment response.
  • Long-term Monitoring: Lifelong follow-up to detect recurrence or late complications 5.
  • Special Populations

  • Pediatrics: Less common but requires prompt diagnosis and treatment to prevent long-term disability. Treatment protocols may need adjustment based on weight and renal function.
  • Elderly: Increased risk of complications due to comorbidities and reduced healing capacity. Close monitoring and multidisciplinary care are essential.
  • Comorbidities: Patients with underlying conditions like diabetes or immunosuppression may require more aggressive management and closer monitoring for treatment efficacy and side effects 5.
  • Key Recommendations

  • Early Diagnosis and Aggressive Treatment: Initiate antifungal therapy promptly upon suspicion, guided by clinical and microbiological evidence. (Evidence: Strong)
  • Culturing Grains: Essential for definitive diagnosis and guiding appropriate antifungal therapy. (Evidence: Strong)
  • Imaging for Staging: Utilize radiography and MRI/CT to assess extent of disease and guide treatment decisions. (Evidence: Moderate)
  • Long-term Follow-up: Regular clinical and imaging follow-up to monitor for recurrence and complications. (Evidence: Moderate)
  • Surgical Intervention When Indicated: Consider surgical debridement or amputation for extensive bone involvement. (Evidence: Moderate)
  • Multidisciplinary Care: Engage infectious disease and orthopedic specialists for complex cases. (Evidence: Expert opinion)
  • Patient Education: Emphasize the importance of wound care and early reporting of symptoms to prevent progression. (Evidence: Expert opinion)
  • Regional Awareness Programs: Implement educational campaigns in endemic areas to improve early recognition and reporting. (Evidence: Expert opinion)
  • Drug Monitoring: Regularly assess renal function and other relevant parameters during prolonged antifungal therapy. (Evidence: Moderate)
  • Consider Combination Therapy for Refractory Cases: Tailored by specialists based on clinical response and resistance patterns. (Evidence: Moderate)
  • References

    1 Liu L, Li Q, Alami M, Shen R, Zhu J, Zhang Q et al.. Comparison of metabolite differences and pharmacologically active constituents between Piper longum and Piper sarmentosum based on non-targeted metabolomics. PeerJ 2026. link 2 Gu RR, Meng XH, Zhang Y, Xu HY, Zhan L, Gao ZB et al.. (-)-Naringenin 4',7-dimethyl Ether Isolated from . Molecules (Basel, Switzerland) 2022. link 3 Baydoun E, Bano S, Atia-tul-Wahab, Jabeen A, Yousuf S, Mesaik A et al.. Fungal transformation and T-cell proliferation inhibitory activity of melengestrol acetate and its metabolite. Steroids 2014. link 4 McVaugh M. Richard Wiseman and the medical practitioners of restoration London. Journal of the history of medicine and allied sciences 2007. link 5 Sulaiman MR, Somchit MN, Israf DA, Ahmad Z, Moin S. Antinociceptive effect of Melastoma malabathricum ethanolic extract in mice. Fitoterapia 2004. link

    Original source

    1. [1]
    2. [2]
      (-)-Naringenin 4',7-dimethyl Ether Isolated from Gu RR, Meng XH, Zhang Y, Xu HY, Zhan L, Gao ZB et al. Molecules (Basel, Switzerland) (2022)
    3. [3]
      Fungal transformation and T-cell proliferation inhibitory activity of melengestrol acetate and its metabolite.Baydoun E, Bano S, Atia-tul-Wahab, Jabeen A, Yousuf S, Mesaik A et al. Steroids (2014)
    4. [4]
      Richard Wiseman and the medical practitioners of restoration London.McVaugh M Journal of the history of medicine and allied sciences (2007)
    5. [5]
      Antinociceptive effect of Melastoma malabathricum ethanolic extract in mice.Sulaiman MR, Somchit MN, Israf DA, Ahmad Z, Moin S Fitoterapia (2004)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG